<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522544</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUWIN</org_study_id>
    <nct_id>NCT04522544</nct_id>
  </id_info>
  <brief_title>Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design</brief_title>
  <official_title>A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination&#xD;
      with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of&#xD;
      durvalumab and tremelimumab with either TACE or Y-90 SIRT. Patients will be randomized into&#xD;
      two experimental arms, one receiving SIRT + Durvalumab + Tremelimumab, the other arm&#xD;
      receiving TACE + Durvalumab + Tremelimumab. It will be determined whether the combination of&#xD;
      immunotherapy with SIRT or TACE is more promising.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) [according to RECIST 1.1] at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of allocated subjects with best response of complete or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Time from the date of randomization to the date of first observed disease progression or death (approx. 42 months)</time_frame>
    <description>Time from the date of randomization to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of treatment Date of enrollment until date of death if applicable (up to 42 months until Study Closure)</time_frame>
    <description>Overall survival will be determined as time from the date of treatment allocation to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related SAEs</measure>
    <time_frame>From first patient included until study closure (approx. 42 months after First Patient Included)</time_frame>
    <description>Treatment related serious adverse events rate (SAE) will be determined. All observed toxicities and side effects will be graded according to NCI CTCAE v5.0 for all patients and the degree of association of each with the study treatment assessed and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) as best overall response (BOR) during therapy</measure>
    <time_frame>13 months</time_frame>
    <description>ORR as BOR during therapy will be defined as the proportion of allocated subjects with best response of complete or partial response from date of randomization until disease progression or death from any cause occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>ORR at 6 months for patients who received single treatment of TACE/SIRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life will be assessed by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30 questionnaire) and will be evaluated based on the EORTC QLQ-C30 scoring manual in its most current version at time of data analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Translational research</measure>
    <time_frame>3 months</time_frame>
    <description>Exploratory: Correlation analysis between selected molecular parameters and clinical data to identify molecular biomarkers predictive for outcome are not fully defined at the time this protocol is written. The optional translational research program will consider the latest research data available at the time of analysis. Analysis might comprise (but is not limited to) staining for PD-L1 protein expression on tumor cells using the commercially available IVD Kits (22C3 pharmDx assay, DAKO North America) and lymphocytes, testing for expression of PD-1, PD-L1 and PD-L2, Immune cell infiltrates (IGHM, CD3, CD8, FOXP3, CD68, CD205), Chemokines (CXCL9. CXCL10, CXCL13) and invasion markers (MMP7, MMP9) and assessing circulating nucleic acids and tumor specific transcripts.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Y-90 SIRT + Tremelimumab + Durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE + Tremelimumab + Durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>300 mg Tremelimumab C1D1</description>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)</description>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Y-90 SIRT</intervention_name>
    <description>Locoregional therapy will be performed as a standard-of-care procedure</description>
    <arm_group_label>SIRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Locoregional therapy will be performed as a standard-of-care procedure</description>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving written informed consent and any locally-required authorization (EU&#xD;
             Data Privacy Directive in the EU) obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations.&#xD;
&#xD;
          2. Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          3. Body weight &gt; 30 kg.&#xD;
&#xD;
          4. Multinodular or large, solitary HCC, not eligible for resection or local ablation.&#xD;
&#xD;
          5. Histologically confirmed diagnosis of HCC.&#xD;
&#xD;
          6. Scheduled to receive locoregional therapy as standard of care.&#xD;
&#xD;
          7. At least one measurable site of disease as defined by RECIST 1.1criteria with spiral&#xD;
             CT scan or MRI.&#xD;
&#xD;
          8. No prior systemic anti-cancer therapy.&#xD;
&#xD;
          9. Child-Pugh A.&#xD;
&#xD;
         10. Performance status (PS) ≤ 1 (ECOG scale).&#xD;
&#xD;
         11. Life expectancy of at least 12 weeks.&#xD;
&#xD;
         12. Adequate blood count, liver-enzymes, and renal function:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ANC ≥1.5 (or 1.0) x (&gt; 1500 per&#xD;
                  mm3), platelets ≥100 (or 75) x 109/L (&gt;75,000 per mm3);&#xD;
&#xD;
               -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN);&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are&#xD;
                  present, in which case it must be ≤5x ULN;&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 1.25.&#xD;
&#xD;
         13. Albumin ≥ 31 g/dL.&#xD;
&#xD;
         14. Measured creatinine clearance (CL) &gt;40 mL/min or Calculated creatinine clearance CL&gt;40&#xD;
             mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine&#xD;
             collection for determination of creatinine clearance.&#xD;
&#xD;
         15. Female patients with reproductive potential must have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to start of trial and must use two effective forms&#xD;
             of contraception if sexually active.&#xD;
&#xD;
         16. Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
             failure rate of less than 1% per year. Men receiving IMP and who are sexually active&#xD;
             with WOCBP will be instructed to adhere to contraception for a period of 7 months&#xD;
             after the last dose of investigational products (durvalumab and tremelimumab). Women&#xD;
             who are not of childbearing potential (i.e. who are postmenopausal or surgically&#xD;
             sterile) as well as azoospermic men do not require contraception).&#xD;
&#xD;
         17. If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV)&#xD;
             infection, meets the following criteria:&#xD;
&#xD;
               -  Patients with HBV or HCV infection should be monitored for viral levels during&#xD;
                  study participation;&#xD;
&#xD;
               -  Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV&#xD;
                  DNA should have HBV DNA &lt; 100 IU/ml and should be managed per local treatment&#xD;
                  guidelines. Controlled (treated) hepatitis B subjects will be allowed if they&#xD;
                  started treatment at the time point of enrollment into the study by the latest&#xD;
                  and treatment is continued during study participation and for ≥ 6 months after&#xD;
                  end of study treatment;&#xD;
&#xD;
               -  HCV patients with advanced HCC are mostly not treated for their HCV infection.&#xD;
                  However, patients treated for HCV are considered suitable for inclusion if&#xD;
                  antiviral therapy has been completed prior to first administration of study drug.&#xD;
&#xD;
         18. Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diffuse HCC or presence of vascular invasion or extrahepatic spread with the following&#xD;
             exception:&#xD;
&#xD;
             o Invasion of a segmental portal vein or hepatic veins.&#xD;
&#xD;
          2. Patients with advanced liver disease as defined below:&#xD;
&#xD;
             o liver cirrhosis with stage Child Pugh B and C.&#xD;
&#xD;
          3. Any contraindications for hepatic embolization procedures:&#xD;
&#xD;
               -  Known hepatofugal blood flow;&#xD;
&#xD;
               -  Known porto-systemic shunt;&#xD;
&#xD;
               -  Impaired clotting test (platelet count &lt; 70 Thsd/L, INR &gt; 1.25);&#xD;
&#xD;
               -  Renal failure/insufficiency requiring hemo-or peritoneal dialysis;&#xD;
&#xD;
               -  Known severe atheromatosis;&#xD;
&#xD;
               -  Total thrombosis or total invasion of the main branch of the portal vein.&#xD;
&#xD;
          4. Locoregional therapies ongoing or completed &lt; 4 weeks prior to the baseline scan.&#xD;
&#xD;
          5. History of cardiac disease:&#xD;
&#xD;
               -  Congestive heart failure &gt; New York Heart Association (NYHA) class 2;&#xD;
&#xD;
               -  Active coronary artery disease (CAD) (myocardial infarction ≥ 6 months prior to&#xD;
                  study entry is allowed);&#xD;
&#xD;
               -  Cardiac arrhythmias (Grade &gt; 2 NCI-CTCAE Version 5.0) which are poorly controlled&#xD;
                  with anti-arrhythmic therapy or requiring pace maker;&#xD;
&#xD;
               -  Uncontrolled hypertension;&#xD;
&#xD;
               -  Clinically significant gastrointestinal bleeding within 4 weeks prior to start of&#xD;
                  study drug.&#xD;
&#xD;
          6. Thrombotic or embolic events such as cerebrovascular accident (including transient&#xD;
             ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months&#xD;
             prior to the first dose of study drug with the exception of thrombosis of a segmental&#xD;
             portal vein.&#xD;
&#xD;
          7. Prior, systemic anti-cancer therapy, radiotherapy administered &lt; 4 weeks prior to&#xD;
             study entry, endocrine- or immunotherapy or use of other investigational agents.&#xD;
&#xD;
          8. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab or tremelimumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses not to exceed &lt;&lt;10 mg/day&gt;&gt; of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
          9. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:&#xD;
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to&#xD;
             30 days after the last dose of IP.&#xD;
&#xD;
         10. Major surgery within 4 weeks of starting the study and patients must have recovered&#xD;
             from effects of major surgery.&#xD;
&#xD;
         11. Patients with second primary cancer, except adequately treated basal skin cancer or&#xD;
             carcinoma in-situ of the cervix, unless curatively treated and disease-free for 3&#xD;
             years or longer.&#xD;
&#xD;
         12. Any co-existing medical condition that in the investigator's judgement will&#xD;
             substantially increase the risk associated with the patient's participation in the&#xD;
             study.&#xD;
&#xD;
         13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs or compromise the ability of the patient to give written&#xD;
             informed consent&#xD;
&#xD;
         14. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, Patients with a past or resolved HBV infection (defined as the presence&#xD;
             of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients&#xD;
             positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction&#xD;
             is negative for HCV RNA&#xD;
&#xD;
         15. History of allogenic organ transplantation.&#xD;
&#xD;
         16. Psychiatric disorders or altered mental status precluding understanding of the&#xD;
             informed consent process and/or compliance with the study protocol.&#xD;
&#xD;
         17. Symptomatic brain metastases. A scan to confirm the absence of brain metastases is&#xD;
             required in the presence of corresponding symptoms.&#xD;
&#xD;
         18. Pregnant or breast-feeding women.&#xD;
&#xD;
         19. Immunocompromised patients, e.g. patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
         20. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone&#xD;
&#xD;
         21. Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the&#xD;
             product.&#xD;
&#xD;
         22. Is currently participating or has participated in a study of an investigational agent&#xD;
             or has used an investigational device within 4 weeks prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
         23. Patient who has been incarcerated or involuntarily&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Vogel, Prof. Dr.</last_name>
    <phone>+49 511 5326</phone>
    <phone_ext>760</phone_ext>
    <email>Vogel.Arndt@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johanna Riedel, Dr.</last_name>
    <phone>+49 7601</phone>
    <phone_ext>4635</phone_ext>
    <email>riedel.johanna@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arndt Vogel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Marquardt, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

